New Two-Pronged drug tested to shrink tumors before cancer surgery
NCT ID NCT04556253
Summary
This study is testing whether an immunotherapy drug called AK104, given before and after surgery, can help people with specific types of locally advanced stomach or colorectal cancer. The goal is to see if the treatment can completely eliminate the cancer cells in the removed tumor. Participants receive the drug for three cycles before their operation and may continue it for up to six months afterward.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MSI-H/DMMR GASTRIC CARCINOMA AND COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, 100142, China
Conditions
Explore the condition pages connected to this study.